First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

NCT02937116 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

233

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer, Solid Tumor

Interventions

DRUG: IBI308
DRUG: IBI308\Cisplatinum\Pemetrexed
DRUG: IBI308\cisplatin\gemcitabine
DRUG: IBI308\oxaliplatin\capecitabine
DRUG: IBI308\etoposide\cisplatin
DRUG: IBI308\irinotecan\5-FU

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.